Brief: Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
19/03/2026 11:57
March 19 (Reuters) - Biohaven Ltd BHVN.N: BIOHAVEN'S PHASE 2 OBESITY STUDY WITH TALDEFGROBEP ALFA, A NOVEL MYOSTATIN-ACTIVIN PATHWAY INHIBITOR, COMPLETES ENROLLMENT Source text: ID:nPn9VHmYna Further company coverage: BHVN.N ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean